Bullous Pemphigoid and Chronic Kidney Disease: Association and Management

Diagnosis and Treatment

The British Journal of Dermatology recommends a modified pre-therapy evaluation for patients with chronic kidney disease (CKD) and suspected bullous pemphigoid, considering the patient's reduced kidney function 1, 2
Complete blood count, creatinine, and electrolytes (especially important for CKD patients to adjust medication doses) should be performed 1, 2, 3
Skin biopsy with direct immunofluorescence is necessary for confirmation 1, 4
ELISA for anti-BP180 and anti-BP230 IgG autoantibodies should be conducted 1, 2
The American Academy of Dermatology suggests that topically applied corticosteroids remain the first-line treatment for localized/limited pemphigoid in CKD patients, as systemic absorption is minimal and no dose adjustment is required 1, 3
Clobetasol propionate 0.05% cream, 30-40 g/day, is recommended for patients with CKD 1, 3
Systemic corticosteroids should be used with extreme caution in CKD patients with extensive bullous pemphigoid, due to the increased risk of side effects 1, 2
Prednisone 0.5-0.75 mg/kg/day is recommended as the initial dose for CKD patients, with close monitoring of electrolytes, glucose, and blood pressure 1, 3
Azathioprine can be used as a steroid-sparing therapy, but its use requires caution in CKD patients, and the dose needs to be adjusted according to kidney function 5
The National Kidney Foundation suggests that CKD patients with bullous pemphigoid require close monitoring of kidney function, electrolytes, and medication side effects 1, 2, 3

Bullous pemphigoid is a chronic disease that can last for several years and has a tendency to recur 1, 2
The disease usually remits within 5 years 5
Regular screening for associated comorbidities (hypertension, diabetes, basal cell carcinoma, obstructive sleep apnea) is recommended for all pemphigoid patients 1, 2, 3